Top

Published in:

01-09-2018 | Laboratory Investigation

Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals

Authors: Yan-Xi Li, Abudumijiti Aibaidula, Zhifeng Shi, Hong Chen, Kay Ka-Wai Li, Nellie Yuk-Fei Chung, Ryan Rui Yang, Danny Tat-Ming Chan, Wai Sang Poon, Ka Lok Ryan Lee, Ying Mao, Jinsong Wu, Aden Ka-yin Chan, Liangfu Zhou, Ho-Keung Ng

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Although oligodendrogliomas appear histologically similar in adult and pediatric patients, the latter have only been rarely studied and most of those studies did not have long follow-up. We examined 55 oligodendroglial tumors from pediatric and teenage patients for their biomarkers with formalin-fixed paraffin-embedded tissues and studied their survival status. None of the tumors harbored 1p/19q codeletion or IDH mutation. Mutations in TERTp (4%), BRAF (11%), FGFR1 (3%) and H3F3A (5%), fusions of BRAF (8%) and FGFR1 (8%) were found sparingly and almost all in a mutually exclusive manner. Molecular events were exclusively found in tumors with classic oligodendroglial histology. Survival analysis showed remarkably excellent prognosis compared to the adult counterparts. 5-year overall survival was 95% in our cohort with median follow-up of 8.1 years and in nine patients with follow-up more than 10 years, the 10-year overall survival was 100%. The 5-year and 10-year progression-free survivals of our cohort were 89 and 77%, respectively. FGFR1 fusion seemed to confer a poor prognosis in pediatric oligodendrogliomas. Patients receiving adjuvant chemotherapy (p = 0.046) or harboring Grade II histology (p < 0.001) had longer interval to recurrence. Our study demonstrated the distinct indolent clinical course of pediatric and teenage oligodendrogliomas compared to the adult tumors. Molecular markers commonly seen in adult oligodendrogliomas and other pediatric low-grade gliomas were only rarely seen. Since there is no clinical or molecular evidence suggesting that pediatric “oligodendrogliomas” are the same as adult oligodendrogliomas albeit histologic similarity, a case can be made for their separation from adult oligodendrogliomas in the next WHO classification.

Available only for authorised users

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C (2011) Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 13(10):1099–1106. https://doi.org/10.1093/neuonc/nor146 CrossRefPubMedPubMedCentral

Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B, Jackson S, Cohen K, Burger PC (2014) Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 38(8):1058–1070. https://doi.org/10.1097/PAS.0000000000000221 CrossRefPubMedPubMedCentral

Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA (2005) Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 109(4):387–392. https://doi.org/10.1007/s00401-004-0976-2 CrossRefPubMed

Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL III (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62(5):530–537. https://doi.org/10.1093/jnen/62.5.530 CrossRefPubMed

Creach KM, Rubin JB, Leonard JR, Limbrick DD, Smyth MD, Dacey R, Rich KM, Dowling JL, Grubb RL Jr, Linette GP, King AA, Michalski JM, Park TS, Perry A, Simpson JR, Mansur DB (2012) Oligodendrogliomas in children. J Neurooncol 106(2):377–382. https://doi.org/10.1007/s11060-011-0674-6 CrossRefPubMed

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, Ellison DW, St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome P (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45(6):602–612. https://doi.org/10.1038/ng.2611 CrossRefPubMedPubMedCentral

Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45(8):927–932. https://doi.org/10.1038/ng.2682 CrossRefPubMedPubMedCentral

Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677. https://doi.org/10.1158/0008-5472.CAN-08-2097 CrossRefPubMedPubMedCentral

10.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. https://doi.org/10.1007/s00401-011-0802-6 CrossRefPubMed

11.

Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H, Boggs K, Shao Y, Rusch M, Becksfort J, Gupta P, Wang S, Lee RP, Brat D, Peter Collins V, Dahiya S, George D, Konomos W, Kurian KM, McFadden K, Serafini LN, Nickols H, Perry A, Shurtleff S, Gajjar A, Boop FA, Klimo PD Jr, Mardis ER, Wilson RK, Baker SJ, Zhang J, Wu G, Downing JR, Tatevossian RG, Ellison DW (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131(6):833–845. https://doi.org/10.1007/s00401-016-1539-z CrossRefPubMedPubMedCentral

12.

Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, de Seixas Alves MT, Capellano AM, Saba-Silva N, Cavalheiro S, Cerutti JM, Toledo SR (2014) Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol 117(2):235–242. https://doi.org/10.1007/s11060-014-1398-1 CrossRefPubMed

13.

Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, Suri V, Sharma MC, Suri A, Sarkar C (2015) Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 208(3):91–95. https://doi.org/10.1016/j.cancergen.2015.01.009 CrossRefPubMed

14.

Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430–436. https://doi.org/10.1593/tlo.12328 CrossRefPubMedPubMedCentral

15.

Nauen D, Haley L, Lin MT, Perry A, Giannini C, Burger PC, Rodriguez FJ (2016) Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas. Brain Pathol 26(2):206–214. https://doi.org/10.1111/bpa.12291 CrossRefPubMed

16.

Van den Bent MJ, Reni M, Gatta G, Vecht C (2008) Oligodendroglioma. Crit Rev Oncol Hematol 66(3):262–272. https://doi.org/10.1016/j.critrevonc.2007.11.007 CrossRefPubMed

17.

Scheie D, Meling TR, Cvancarova M, Skullerud K, Mork S, Lote K, Eide TJ, Helseth E, Beiske K (2011) Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol 13(11):1225–1233. https://doi.org/10.1093/neuonc/nor114 CrossRefPubMedPubMedCentral

18.

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):1–62. https://doi.org/10.1093/neuonc/not151 CrossRef

19.

Razack N, Baumgartner J, Bruner J (1998) Pediatric oligodendrogliomas. Pediatr Neurosurg 28(3):121–129. https://doi.org/10.1159/000028635 CrossRefPubMed

20.

Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL (2007) Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol 83(1):1–8. https://doi.org/10.1007/s11060-006-9299-6 CrossRefPubMed

21.

Zhang RQ, Shi Z, Chen H, Chung NY, Yin Z, Li KK, Chan DT, Poon WS, Wu J, Zhou L, Chan AK, Mao Y, Ng HK (2016) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7(4):5030–5041. https://doi.org/10.18632/oncotarget.5456 PubMedCrossRef

22.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon II JE, DD YHaB (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5(6): 1515–1525. https://doi.org/10.18632/oncotarget.1765 PubMedPubMedCentralCrossRef

23.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337(6099):1231–1235. https://doi.org/10.1126/science.1220834 CrossRefPubMedPubMedCentral

24.

Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3(6):636–647. https://doi.org/10.1158/2159-8290.CD-13-0050 CrossRefPubMedPubMedCentral

25.

Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, Ji H, Sun Y, Chen H (2014) FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 20(15):4107–4114. https://doi.org/10.1158/1078-0432.CCR-14-0284 CrossRefPubMed

26.

Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R (2013) Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230(3):270–276. https://doi.org/10.1002/path.4209 CrossRefPubMed

27.

Parker BC, Engels M, Annala M, Zhang W (2014) Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol 232(1):4–15. https://doi.org/10.1002/path.4297 CrossRefPubMed

28.

Shi YJ, Tsang JY, Ni YB, Chan SK, Chan KF, Tse GM (2015) FGFR1 is an adverse outcome indicator for luminal A breast cancers. Oncotarget 7(4):5063–5073. https://doi.org/10.18632/oncotarget.6563 PubMedCentralCrossRef

29.

Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM (2016) FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 22(15):3884–3893. https://doi.org/10.1158/1078-0432.CCR-15-1874 CrossRefPubMed

30.

Becker AP, Scapulatempo-Neto C, Carloni AC, Paulino A, Sheren J, Aisner DL, Musselwhite E, Clara C, Machado HR, Oliveira RS, Neder L, Varella-Garcia M, Reis RM (2015) KIAA1549:BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J Neuropathol Exp Neurol 74(7):743–754. https://doi.org/10.1097/NEN.0000000000000213 CrossRefPubMedPubMedCentral

31.

Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17(14):4790–4798. https://doi.org/10.1158/1078-0432.CCR-11-0034 CrossRefPubMed

32.

Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18(2):184–187. https://doi.org/10.1038/ng0298-184 CrossRefPubMed

33.

Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2(5):367–376. https://doi.org/10.1016/S1535-6108(02)00180-0 CrossRefPubMed

34.

Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, Kudoh S, Tanaka K, Setoyama M, Nagamura F, Asano S, Kamada N (1999) Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93(4):1355–1363PubMed

35.

Rubin B, Chen C, Morgan T, Xiao S, Grier H, Kozakewich H, Perez-Atayde A, Fletcher J (1998) Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153(5):1451–1458. https://doi.org/10.1016/S0002-9440(10)65732-X CrossRefPubMedPubMedCentral

36.

Wai D, Knezevich S, Lucas T, Jansen B, Kay R, Sorensen P (2000) The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19(7):906–915. https://doi.org/10.1038/sj.onc.1203396 CrossRefPubMed

37.

Liu Q, Schwaller J, Kutok J, Cain D, Aster J, Williams I, Gilliland D (2000) Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 19(8):1827–1838. https://doi.org/10.1093/emboj/19.8.1827 CrossRefPubMedPubMedCentral

38.

Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK (2017) Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133(3):417–429. https://doi.org/10.1007/s00401-016-1639-9 CrossRefPubMed

39.

Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, Wiestler OD (1999) The CD34 epitope is expressed in neoplastic and mal- formative lesions associated with chronic, focal epilepsies. Acta Neuropathol 97(5):481–490. https://doi.org/10.1007/s004010051017 CrossRefPubMed

40.

Blumcke I, Lobach M, Wolf HK, Wiestler OD (1999) Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech 46(1): 53–58CrossRefPubMed

41.

Blumcke I, Wiestler OD (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61(7):575–584. https://doi.org/10.1093/jnen/61.7.575 CrossRefPubMed

42.

Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A, Sarkar C (2006) Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol 32(5):461–468. https://doi.org/10.1111/j.1365-2990.2006.00734.x CrossRefPubMed

43.

Reifenberger G, Kaulich K, Wiestler OD, Blumcke I (2003) Expression of the CD34 antigen in pleomorphic xanthoastrocytomas. Acta Neuropathol 105(4): 358–364. https://doi.org/10.1007/s00401-002-0652-3 PubMedCrossRef

44.

Sung CO, Suh YL, Hong SC (2011) CD34 and microtubule-associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non-specific types. Histopathology 59(2):308–317. https://doi.org/10.1111/j.1365-2559.2011.03936.x CrossRefPubMed

45.

Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B, Dean A, McEvoy A, Sisodiya SM, Brandner S (2011) One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 70(10): 859–878. https://doi.org/10.1097/NEN.0b013e3182302475 CrossRefPubMed

46.

Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128(4):551–559. https://doi.org/10.1007/s00401-014-1326-7 CrossRefPubMed

47.

Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nister M, Smits A, Ren ZP (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113(2):129–136. https://doi.org/10.1007/s00401-006-0142-0 CrossRefPubMed

48.

Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, Suter CM, Kaufman K, Lum T, Buckland ME (2015) Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol 129(1):147–149. https://doi.org/10.1007/s00401-014-1353-4 CrossRefPubMed

49.

Huse JT, Diamond EL, Wang L, Rosenblum MK (2015) Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol 129(1):151–153. https://doi.org/10.1007/s00401-014-1359-y CrossRefPubMed

50.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi CJ, Lopez GY, He Y, Friedman HS, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon RE, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA Jr (2012) Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 3(7):709–722. https://doi.org/10.18632/oncotarget.588 CrossRefPubMedPubMedCentral

51.

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126(6):907–915. https://doi.org/10.1007/s00401-013-1195-5 CrossRefPubMed

52.

Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF (2010) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119(5):641–649. https://doi.org/10.1007/s00401-009-0634-9 CrossRefPubMedPubMedCentral

53.

Horbinski C, Miller CR, Perry A (2011) Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 21(1):57–73. https://doi.org/10.1111/j.1750-3639.2010.00453.x CrossRefPubMed

54.

Li Y-X, Shi Z, Aibaidula A, Chen H, Tang Q, Li KK, Chung NY, Chan DT, Poon WS, Mao Y, Wu J, Zhou L, Chan AK, Ng HK (2016) Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget 7(40):64615–64630. https://doi.org/10.18632/oncotarget.11378 PubMedPubMedCentralCrossRef

55.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK (2015) TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol 28(2):177–186. https://doi.org/10.1038/modpathol.2014.94 CrossRefPubMed

56.

Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK (2015) Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget 6(25):20885–20901. https://doi.org/10.18632/oncotarget.4928 PubMedPubMedCentralCrossRef

57.

Ryall S, Krishnatry R, Arnoldo A, Buczkowicz P, Mistry M, Siddaway R, Ling C, Pajovic S, Yu M, Rubin JB, Hukin J, Steinbok P, Bartels U, Bouffet E, Tabori U, Hawkins C (2016) Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun 4(1):93–103. https://doi.org/10.1186/s40478-016-0353-0 CrossRefPubMedPubMedCentral

58.

Ryall S, Arnoldo A, Krishnatry R, Mistry M, Khor K, Sheth J, Ling C, Leung S, Zapotocky M, Guerreiro Stucklin A, Lassaletta A, Shago M, Tabori U, Hawkins C (2017) Multiplex detection of pediatric low-grade glioma signature fusion transcripts and duplications using the nanostring ncounter system. J Neuropathol Exp Neurol 76(7):562–570. https://doi.org/10.1093/jnen/nlx042 CrossRefPubMed

59.

Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Stucklin AG, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Rao AN, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Conter CF, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. https://doi.org/10.1200/JCO.2016.71.8726 PubMedPubMedCentralCrossRef

Title: Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals
Authors: Yan-Xi Li
Abudumijiti Aibaidula
Zhifeng Shi
Hong Chen
Kay Ka-Wai Li
Nellie Yuk-Fei Chung
Ryan Rui Yang
Danny Tat-Ming Chan
Wai Sang Poon
Ka Lok Ryan Lee
Ying Mao
Jinsong Wu
Aden Ka-yin Chan
Liangfu Zhou
Ho-Keung Ng
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2890-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma’s grade and IDH status

GOLPH3 promotes glioma progression via facilitating JAK2–STAT3 pathway activation

Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009–2014

PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population

Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10